Vertex Pharmaceuticals | VRTX - Loan Capital

Stock Price
423.08
Daily Change
-7.06 -1.64%
Monthly
-4.53%
Yearly
-16.96%
Q2 Forecast
421.08

Vertex Pharmaceuticals reported $111.4M in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Arrowhead Research USD 538.1M 323.22M Dec/2025
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Gilead Sciences USD 22.13B 6M Dec/2025
Incyte USD 29.41M 785K Mar/2026
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
J&J USD 37.53B 1.91B Mar/2026
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025